Evaluation of the effectiveness and side effect profile in elderly patients with CRSwNP receiving dupilumab therapy

Introduction Biologica are a highly effective treatment options for severe chronic rhinosinusitis with nasal polyposis (CRSwNP). Little is known about CRSwNP in elderly patients. In the CRSwNP phase 3 study of dupilumab, the maximum age of the patients was 61 years. The aim of this prospective study was to investigate the effectiveness of rhinonasal parameters and the side effect profile in CRSwNP patients after 6 months of dupilumab therapy.